Talphera outlines plan to seek FDA agreement to end NEPHRO enrollment by Dec. 31, 2026, while raising Niyad peak U.S. sales view to over $200M
Source: Seeking Alpha ·
Read the full story at Seeking Alpha
Shared from the GodsView world desk: live wires next to a globe of flights, ships, fires, and quakes.